Tech Company Financing Transactions
Unum Therapeutics Funding Round
Fairmount Funds Management, Acorn Bioventures and Ally Bridge Group participated in a $104.4 million venture round for Unum Therapeutics. The financing was announced on 7/10/2020.
Transaction Overview
Company Name
Announced On
7/10/2020
Transaction Type
Venture Equity
Amount
$104,400,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds from the private placement will be used to advance clinical testing of PLX9486, a highly potent and selective KIT D816V inhibitor, in multiple indications and provide runway beyond 2022.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Cambridge Park Dr. 3100
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chuck Wilson
Chief Financial Officer
John Green
Chief Medical Officer
Jessica Sachs
VP - Human Resources
Erin Schellhammer
VP - Operations
Larry Weiner
VP - R & D
Gregory Motz
VP - Regulatory Affairs
Todd Kenney
Browse more venture capital transactions:
Prev: 7/10/2020: Harbour BioMed venture capital transaction
Next: 7/10/2020: Orpyx Medical Technologies venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs